A newly developed lab-designed molecule, JM2, may offer a promising therapy to combat glioblastoma recurrence by targeting the tumor's most resilient cells. Researchers discovered that glioblastoma stem cells rely on the protein connexin 43's interaction with microtubules--an interaction disrupted by JM2.
A newly developed lab-designed molecule, JM2, may offer a promising therapy to combat glioblastoma recurrence by targeting the tumor's most resilient cells. Researchers discovered that glioblastoma stem cells rely on the protein connexin 43's interaction with microtubules--an interaction disrupted by JM2.
Share this Article
Recommended